Article
Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
Gut - 1 Dec 2003
Lee H C, Suh D J, Ryu S H, Kim H, Shin J W, Lim Y-S, Chung Y-H, Lee Y S
Abstract excerpt
BACKGROUND AND AIMS: Lamivudine induces favourable virological and biochemical responses but post-treatment relapses are frequent, even in patients with hepatitis B e antigen (HBeAg) loss or seroconversion. The aim of this study was to determine whether extended lamivudine therapy for up to 12 months after HBeAg loss/seroconversion could decrease the risk of post-treatment virological relapse. In addition, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.